Immutep Limited
IMMPHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeImmutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The $23.6M market capitalization puts IMMP squarely in micro-cap range for its industry. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Market Cap
$23.6M
Beta
2.30
P/E (TTM)
—
P/E (Fwd)
-0.99
EPS (TTM)
$-7.31
EPS (Fwd)
$-3.23
ROE
-77.3%
ROA
-42.4%
Cash
$68.9M
Total Debt
$1.0M
Free CF
-$37.0M
52W Change
-92.2%
Annual Financials
Cash vs Debt
Where IMMP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMMP finished 210.78% above its 150-day moving average ($1.02) and 117.12% above its 200-day moving average ($1.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMMP overbought or oversold?
At the October 20, 2026 close, IMMP's RSI(14) was 6.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Immutep Limited holds $68.9M in cash against $1.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$37.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -77.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.30 means IMMP is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immutep Limited's trajectory.